Robert E. Waltermire - 12 Dec 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Senior VP, Chief Pharma Dev.
Signature
/s/ Brian J. Lynch*
Issuer symbol
MDGL
Transactions as of
12 Dec 2023
Net transactions value
-$512,604
Form type
4
Filing time
14 Dec 2023, 16:30:08 UTC
Previous filing
02 Mar 2023
Next filing
18 Dec 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $114,296 +1,300 +23% $87.92 6,967 12 Dec 2023 Direct F1
transaction MDGL Common Stock Sale $108,000 -500 -7.2% $216.00 6,467 12 Dec 2023 Direct
transaction MDGL Common Stock Sale $175,200 -800 -12% $219.00 5,667 12 Dec 2023 Direct
transaction MDGL Common Stock Options Exercise $219,800 +2,500 +44% $87.92 8,167 13 Dec 2023 Direct F1
transaction MDGL Common Stock Sale $337,500 -1,500 -18% $225.00 6,667 13 Dec 2023 Direct
transaction MDGL Common Stock Sale $226,000 -1,000 -15% $226.00 5,667 13 Dec 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -1,300 -5.2% $0.000000 23,700 12 Dec 2023 Common Stock 1,300 $87.92 Direct F1
transaction MDGL Stock Option (Right to Buy) Options Exercise $0 -2,500 -11% $0.000000 21,200 13 Dec 2023 Common Stock 2,500 $87.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All shares issued pursuant to the exercise of the options reported herein represent 3,800 shares underlying an overall option award of 35,000 shares. All exercised options had vested. As to the overall option for 35,000 shares, 25% of the shares underlying the option vested on August 2, 2022 and, thereafter, 6.25% of the shares vested, or will vest, on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Remarks:

*As attorney-in-fact for Reporting Person